このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Senseonics Holdings マネジメント

マネジメント基準チェック /24

Senseonics Holdings'の CEO はTim Goodnowで、 Dec2015年に任命され、の在任期間は 8.5年です。の年間総報酬は$ 3.59Mで、 17.1%給与と82.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.86%を直接所有しており、その価値は$ 1.74M 。経営陣と取締役会の平均在任期間はそれぞれ6.7年と7.8年です。

主要情報

Tim Goodnow

最高経営責任者

US$3.6m

報酬総額

CEO給与比率	17.1%
CEO在任期間	8.6yrs
CEOの所有権	0.9%
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	7.8yrs

経営陣の近況

Recent updates

How Much Is Senseonics Holdings' (NYSEMKT:SENS) CEO Getting Paid?

Dec 16

CEO報酬分析

Senseonics Holdings の収益と比較して、Tim Goodnow の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$81m
Dec 31 2023	US$4m	US$613k	-US$60m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	US$57m
Dec 31 2022	US$4m	US$586k	US$142m
Sep 30 2022	n/a	n/a	US$215m
Jun 30 2022	n/a	n/a	US$318m
Mar 31 2022	n/a	n/a	US$34m
Dec 31 2021	US$3m	US$569k	-US$302m
Sep 30 2021	n/a	n/a	-US$489m
Jun 30 2021	n/a	n/a	-US$555m
Mar 31 2021	n/a	n/a	-US$382m
Dec 31 2020	US$3m	US$552k	-US$175m
Sep 30 2020	n/a	n/a	-US$109m
Jun 30 2020	n/a	n/a	-US$105m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$2m	US$536k	-US$116m
Sep 30 2019	n/a	n/a	-US$87m
Jun 30 2019	n/a	n/a	-US$100m
Mar 31 2019	n/a	n/a	-US$101m
Dec 31 2018	US$2m	US$536k	-US$94m
Sep 30 2018	n/a	n/a	-US$103m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$520k	-US$59m

報酬と市場: Timの総報酬 ($USD 3.59M ) は、 US市場 ($USD 1.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Timの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Tim Goodnow (62 yo)

8.6yrs

在職期間

US$3,589,760

報酬

Dr. Timothy T. Goodnow, also known as Tim, Ph D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Timothy Goodnow	President	8.6yrs	US$3.59m	0.92% $ 1.9m
Mukul Jain	Chief Operating Officer	7.5yrs	US$1.56m	0.35% $ 736.9k
Kenneth Horton	General Counsel & Corporate Development Advisor	6.8yrs	US$1.31m	0.23% $ 473.8k
Francine Kaufman	Chief Medical Officer & Director	5.3yrs	データなし	0.21% $ 433.8k
Frederick Sullivan	CFO, Secretary & Treasurer	1.8yrs	データなし	0.10% $ 210.1k

6.8yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: SENSの経営陣は経験豊富で経験豊富です（平均在職期間は6.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Timothy Goodnow	President	8.6yrs	US$3.59m	0.92% $ 1.9m
Francine Kaufman	Chief Medical Officer & Director	4.7yrs	データなし	0.21% $ 433.8k
Douglas Roeder	Independent Non-Management Director	8.6yrs	US$174.75k	0.15% $ 316.0k
Edward Fiorentino	Independent Non-Management Director	8.6yrs	US$169.00k	0.16% $ 328.1k
Stephen DeFalco	Independent Chairman	8.6yrs	US$210.00k	0.32% $ 655.3k
Steven Edelman	Independent Non-Management Director	7.8yrs	US$164.00k	0.15% $ 301.5k
Douglas Prince	Independent Non-Management Director	8.6yrs	US$182.50k	0.12% $ 253.7k
Brian Hansen	Director	less than a year	データなし	データなし
Anthony Raab	Independent Non-Management Director	3.8yrs	US$152.50k	0.087% $ 181.7k
Sharon Larkin	Independent Non-Management Director	2.6yrs	US$159.00k	0.051% $ 105.0k
Koichiro Sato	Director	1.2yrs	データなし	データなし

7.8yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: SENSの取締役会は経験豊富であると考えられます ( 7.8年の平均在任期間)。

Senseonics Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Independent Non-Management Director recently bought US$162k worth of stock

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Senseonics Holdings, Inc. Announces CFO Transition

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Recent updates

Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration

Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024

Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 22%

Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023

Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Independent Non-Management Director recently bought US$162k worth of stock

Price target decreased by 18% to US$1.67

New minor risk - Profitability

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 29%

Price target increased by 35% to US$2.75

Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Senseonics Holdings, Inc. Elects Koichiro Sato as Directors

Consensus estimates of losses per share improve by 33%

Price target increased by 19% to US$2.50

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 33%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022

Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Senseonics Holdings, Inc. Announces CFO Transition

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Chief Operating Officer notifies of intention to sell stock

Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem

Investor sentiment improved over the past week

Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$2.10

Investor sentiment improved over the past week

Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System

Consensus revenue estimates increase by 23%

Price target increased to US$4.25

Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022

Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S

Independent Non-Management Director notifies of intention to sell stock

Consensus revenue estimates fall by 13%

Full year 2021 earnings: EPS misses analyst expectations

Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Price target increased to US$4.17

President recently sold US$1.1m worth of stock

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months

Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Chief Medical Officer & Director notifies of intention to sell stock

Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020)

Independent Non-Management Director exercised options and sold US$410k worth of stock

Independent Non-Management Director recently sold US$457k worth of stock

Consensus forecasts updated

Price target increased to US$2.58

Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.033 loss in 2Q 2020)

Chief Medical Officer & Director notifies of intention to sell stock

Senseonics Holdings, Inc Announces the Results of the Promise Study Evaluating the Accuracy and Safety of the Next Generation Eversense CGM System for Up to 180 Days with Reduced Calibrations

Independent Non-Management Director Peter Klein has left the company

Independent Non-Management Director notifies of intention to sell stock

Consensus forecasts updated

マネジメント基準チェック /24